This week's update features Iovance Biotherapeutics' new cancer immunotherapy candidate IOV-4001 that was recently cleared for clinical trial...

This week’s IND update looks at FT536, a gene-edited natural killer cell therapy developed by Fate Therapeutics for the treatment of multiple solid...

2021 was a very successful year for CRISPR in the medical field. Much of the success comes down to gene editing without double-strand breaks,...

In our first clinical update of 2022, we look at three new IND approvals for gene-edited therapies for life-threatening E. coli infections,...

In this piece, we provide selected highlights from the 63rd American Society of Hematology annual meeting, held from December 11-14th 2021.

Some of the best links we picked up around the internet

CRISPR Therapeutics and ViaCyte announced yesterday that Canada’s medical agency Health Canada has approved their clinical trial application for...

On Monday, Beam Therapeutics announced that the U.S. FDA had cleared BEAM-101 for clinical evaluation as a treatment for sickle cell disease. BEAM-101...